Can You Get Liver Cancer Without Drinking Alcohol?
At a Glance
Yes. Hepatocellular carcinoma can develop without alcohol use. Common contributors include metabolic fatty liver disease (MASLD), chronic hepatitis B or C, and advanced liver scarring (cirrhosis). Care depends mainly on the tumor, liver function, and overall health.
In this answer
4 sections
Yes, absolutely. While heavy alcohol use is a widely recognized cause of liver disease, it is entirely possible to develop hepatocellular carcinoma (HCC) without ever drinking alcohol [1]. In fact, the landscape of liver cancer is changing. Today, conditions related to your body’s metabolism and chronic viral infections are among the leading causes of HCC worldwide [1][2]. It can be confusing and frustrating to receive an HCC diagnosis if you don’t drink, but liver cancer often arises from other long-term conditions.
The Rise of Metabolic Liver Disease
One of the most common reasons someone who doesn’t drink might develop HCC is a condition known as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [1]. MASLD occurs when excess fat builds up in the liver alongside at least one metabolic risk factor (such as elevated blood sugar, blood pressure, or weight). While doctors assess alcohol use and metabolic conditions separately, it is possible for both to affect the liver at the same time.
MASLD is incredibly common, affecting roughly one-third of adults globally [3]. Most people with MASLD will never develop liver cancer. However, as rates of obesity, insulin resistance, and type 2 diabetes (a condition where your body struggles to regulate blood sugar) have risen, MASLD has become a rapidly growing contributor to HCC [4][5]. Having type 2 diabetes or obesity can amplify your risk, as these conditions create chronic inflammation and oxidative stress in the liver [6].
Most HCC arises in a liver that has become heavily scarred, a condition known as cirrhosis. While the risk is highest when advanced scarring or cirrhosis is present, MASLD is one of the conditions that can sometimes be associated with HCC even before cirrhosis develops [7].
Viral Hepatitis B and C
Another major cause of HCC in non-drinkers is chronic infection with the hepatitis B (HBV) or hepatitis C (HCV) viruses [1]. These viruses can live in the body for decades without causing obvious symptoms, quietly creating persistent inflammation and liver damage [8].
- Hepatitis B: This virus can directly alter the DNA of your liver cells, which means it can also cause HCC even if you do not have severe liver scarring or cirrhosis [9]. Even if the virus is suppressed with medication, some risk of liver cancer remains [10].
- Hepatitis C: HCV promotes cancer through long-term injury and inflammation that leads to fibrosis (scarring) and cirrhosis [8]. While modern treatments can cure hepatitis C, the risk for liver cancer does not drop to zero, especially if advanced scarring was already present before the virus was cured [11][12].
Other Non-Alcohol Risk Factors
While metabolic disease and viral hepatitis are the most common non-alcohol-related causes, other factors can lead to HCC. Sometimes, multiple risk factors coexist, and occasionally, no single clear cause is ever found. Other specific causes include [2]:
- Hemochromatosis: A genetic condition where the body absorbs and stores too much iron.
- Autoimmune hepatitis: A condition where the body’s immune system mistakenly attacks the liver.
- Aflatoxin exposure: Exposure to a natural toxin produced by certain molds found on agricultural crops, which is primarily a risk in specific regions of the world.
What This Means for Your Care
Your HCC treatment plan is driven primarily by the size and spread of the tumor, your overall liver function, and your general health. However, understanding the underlying cause of your liver disease is still helpful for managing your broader health and planning follow-up care [13].
- Metabolic Health: If your HCC is tied to MASLD or metabolic syndrome, your care team may suggest strategies to manage your blood sugar and cardiovascular health [13]. However, do not start rapid weight-loss diets or unmonitored supplements. Always work with your oncology team and a dietitian, especially since cancer treatments can cause poor appetite and unintended weight loss.
- Viral Hepatitis Care: All HCC patients should be tested for HBV and HCV. If you have chronic hepatitis B, your team will likely prescribe antiviral therapy to prevent the virus from reactivating during cancer treatment [10]. If you have hepatitis C, your hepatologist and oncologist will coordinate the best timing for antiviral treatment.
- Follow-Up Imaging: After an HCC diagnosis, you will need ongoing follow-up imaging. This schedule is highly individualized based on your cancer treatment, tumor stage, and liver health [12]. Ask your oncology team for the specific imaging schedule that is right for you.
Common questions in this guide
Can hepatocellular carcinoma happen if I have never consumed alcohol?
What non-alcohol-related conditions can increase liver cancer risk?
Can fatty liver disease or diabetes lead to liver cancer before cirrhosis?
Does hepatitis treatment eliminate the risk of liver cancer?
What should be checked after an HCC diagnosis if I do not drink?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What tests were used to determine the underlying causes of my liver disease, such as full testing for hepatitis B and C?
- 2.If I have metabolic risk factors like diabetes, how can we safely manage them during my cancer treatment?
- 3.What is my current liver fibrosis stage, or my Child-Pugh score, and does it indicate that I have cirrhosis?
- 4.Will I need to start or adjust any antiviral medications for hepatitis B or C during my cancer therapy?
- 5.Based on my specific cancer treatment and tumor stage, what will my follow-up imaging schedule look like?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (13)
- 1
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment.
Hwang SY, Danpanichkul P, Agopian V, et al.
Clinical and molecular hepatology 2025; (31(Suppl)):S228-S254 doi:10.3350/cmh.2024.0824.
PMID: 39722614 - 2
A global view of hepatocellular carcinoma: trends, risk, prevention and management.
Yang JD, Hainaut P, Gores GJ, et al.
Nature reviews. Gastroenterology & hepatology 2019; (16(10)):589-604 doi:10.1038/s41575-019-0186-y.
PMID: 31439937 - 3
An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillance.
Armandi A, Rosso C, Caviglia GP, Bugianesi E
Metabolism: clinical and experimental 2025; (162()):156080 doi:10.1016/j.metabol.2024.156080.
PMID: 39571891 - 4
Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.
Wang Y, Fleishman JS, Li T, et al.
Frontiers in pharmacology 2023; (14()):1336216 doi:10.3389/fphar.2023.1336216.
PMID: 38313077 - 5
Risk Assessment and Prediction of Hepatocellular Carcinoma in Noncirrhotic Metabolic Dysfunction-Associated Steatotic Liver Disease.
Mitten EK, Portincasa P, Baffy G
International journal of molecular sciences 2026; (27(7)) doi:10.3390/ijms27073241.
PMID: 41977422 - 6
Metabolic dysfunction-associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad.
Caturano A, Erul E, Nilo R, et al.
European journal of clinical investigation 2025; e70132 doi:10.1111/eci.70132.
PMID: 41071622 - 7
MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges.
Phoolchund AGS, Khakoo SI
Cancers 2024; (16(2)) doi:10.3390/cancers16020259.
PMID: 38254750 - 8
Chronic Hepatitis C in the Direct-Acting Antivirals Era: Carcinogenesis and Clinical Implications.
Aydin Y, Kurt R, Tahan V, Daglilar E
Diseases (Basel, Switzerland) 2025; (13(12)) doi:10.3390/diseases13120393.
PMID: 41439934 - 9
Viral hepatitis and liver cancer.
Ringelhan M, McKeating JA, Protzer U
Philosophical transactions of the Royal Society of London. Series B, Biological sciences 2017; (372(1732)) doi:10.1098/rstb.2016.0274.
PMID: 28893941 - 10
HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC, Wong GL, Chan HL, et al.
Journal of hepatology 2019; (70(3)):361-370 doi:10.1016/j.jhep.2018.10.014.
PMID: 30367899 - 11
Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis.
Bang CS, Song IH
BMC gastroenterology 2017; (17(1)):46 doi:10.1186/s12876-017-0606-9.
PMID: 28376711 - 12
Unmet Needs in the Post-Direct-Acting Antiviral Era: Hepatocarcinogenesis After Hepatitis C Virus Eradication.
Przybyszewski EM, Chung RT
The Journal of infectious diseases 2023; (228(Suppl 3)):S226-S231 doi:10.1093/infdis/jiac447.
PMID: 37703341 - 13
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
, ,
Journal of hepatology 2024; (81(3)):492-542 doi:10.1016/j.jhep.2024.04.031.
PMID: 38851997
This page is for informational purposes only and does not constitute medical advice. Your oncology and liver specialists can explain your individual HCC risk factors, test results, and care plan.
Get notified when new evidence is published on Adult hepatocellular carcinoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.